4th Jul 2016 07:26
LONDON (Alliance News) - Oncimmune Holdings PLC on Monday said it has signed research agreements with private research company Egybiotech and Aarhus University Hospital in Denmark to further validate its EarlyCDT platform technology in liver and ovarian cancer.
The early cancer detection company said Egybiotech and Aarhus will provide it with prospectively collected blood samples and associated clinical data on each patient, in a bid to further clinically validate the company's EarlyCDT platform technology, currently in development, in liver and ovarian cancer.
Oncimmune said it will use the samples to validate panels of autoantibodies as diagnostic tests capable of distinguishing between malignant and non-malignant liver and ovarian diseases, particularly at an early stage.
"Current biomarkers for liver and ovarian cancer perform poorly and our EarlyCDT technology has the potential to allow earlier diagnosis of these serious diseases and improve patient outcomes. The agreements are a significant further step in the final clinical validation of EarlyCDT liver and ovarian and will enable us to remain on track towards the goal of launching the tests commercially in 2017," said Chief Executive Geoffrey Hamilton-Fairley.
Shares in Oncimmune were up 3.1% at 121.70 pence on Monday morning.
By Hannah Boland; [email protected]; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oncimmune